Novo Nordisk has announced encouraging Phase 3 clinical trial results for CagriSema, an investigational once-weekly treatment designed for adults living with type 2 diabetes. Data presented at the 2026 American Diabetes Association Scientific Sessions revealed significant improvements in both blood sugar control and body weight reduction across three large studies within the REIMAGINE clinical program.
The findings highlight the potential of CagriSema to become a new treatment option for people with type 2 diabetes who need better glucose management while also addressing excess body weight, a common challenge associated with the disease.
CagriSema is an experimental combination therapy that brings together two active components:
Both hormones play important roles in regulating appetite, food intake, and blood sugar levels. By combining these mechanisms, researchers aim to create a treatment that delivers stronger metabolic benefits than either therapy alone.
The medication is administered as a once-weekly injection and is currently being evaluated for both type 2 diabetes and obesity management.
The REIMAGINE program consists of several Phase 3 trials designed to evaluate the effectiveness and safety of CagriSema in adults with type 2 diabetes at different stages of treatment.
Three major studies were recently presented:
Each trial assessed changes in HbA1c levels, which measure long-term blood sugar control, along with changes in body weight.
The REIMAGINE 1 study included adults with type 2 diabetes who were not adequately controlled through diet and exercise alone.
After 40 weeks of treatment, participants receiving the higher-dose version of CagriSema experienced:
In contrast, the placebo group showed minimal changes in both blood sugar levels and weight.
Researchers noted that these results demonstrate meaningful clinical benefits for patients in the earlier stages of diabetes treatment.
The largest study in the program, REIMAGINE 2, enrolled more than 2,700 participants with type 2 diabetes who were already taking metformin, with or without SGLT2 inhibitors.
This trial compared CagriSema with several alternatives, including semaglutide alone, cagrilintide alone, and placebo.
Key findings included:
Participants receiving the higher-dose CagriSema achieved an average HbA1c reduction of nearly 1.9 percentage points and experienced average weight loss exceeding 14%.
These results suggest that combining amylin and GLP-1 pathways may provide stronger metabolic benefits than targeting either pathway independently.
The REIMAGINE 3 study focused on adults with type 2 diabetes who were already using daily basal insulin therapy.
Managing diabetes in this population can be particularly challenging because insulin treatment is often associated with weight gain and complex blood sugar fluctuations.
After 40 weeks, patients receiving higher-dose CagriSema experienced:
Meanwhile, participants in the placebo group showed substantially smaller improvements and experienced slight weight gain.
The findings indicate that CagriSema may offer meaningful benefits even for patients with more advanced diabetes requiring insulin support.
Type 2 diabetes affects millions of people worldwide and is frequently linked to obesity and excess body weight. Effective treatment often requires balancing blood sugar control with weight management.
Many existing therapies help lower glucose levels, but achieving significant weight reduction simultaneously remains a challenge for many patients.
The latest data suggest that CagriSema could potentially address both concerns through a single weekly treatment. If future regulatory reviews are successful, the therapy may offer healthcare providers an additional option for patients seeking comprehensive metabolic management.
As with many medications in the GLP-1 class, gastrointestinal side effects were the most commonly reported adverse events across all studies.
Frequently reported issues included:
Most side effects were consistent with expectations for therapies affecting appetite and digestion.
A small percentage of participants discontinued treatment because of adverse events. Overall, researchers reported that the safety findings aligned with the known profiles of the individual components used in the combination therapy.
Researchers involved in the clinical program emphasized the importance of exploring multiple biological pathways to improve diabetes management.
By combining the effects of amylin and GLP-1 receptor activation, CagriSema aims to support:
Experts believe this dual-mechanism approach could represent an important advancement in the treatment landscape for type 2 diabetes.
Novo Nordisk continues to advance the development of CagriSema through additional studies and regulatory reviews.
The company has already submitted a New Drug Application to the U.S. Food and Drug Administration for CagriSema as a weight management treatment. Regulatory decisions are expected in the coming months.
Additional trial results, including comparisons against other leading diabetes and obesity medications, are expected to provide further insight into the therapy's long-term potential.
The REIMAGINE Phase 3 program has delivered encouraging evidence that CagriSema may help adults with type 2 diabetes achieve meaningful improvements in both blood sugar control and body weight management.
Across multiple patient populations, including those newly treated and those already using insulin, the investigational therapy consistently demonstrated strong efficacy results. While regulatory approval is still pending, the data presented so far position CagriSema as one of the most closely watched developments in diabetes care.
As the prevalence of type 2 diabetes continues to rise globally, innovative treatments that address both glucose control and weight reduction could play an increasingly important role in improving patient outcomes.
Novo Nordisk REIMAGINE 1, REIMAGINE 2, and REIMAGINE 3 Phase 3 clinical trial results presented at the 2026 American Diabetes Association Scientific Sessions.
This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. CagriSema is an investigational therapy and may not be approved for use in all regions. Patients should consult a qualified healthcare professional before making any decisions regarding diabetes treatment or medication changes.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.